Episode 65
Could Psychedelic-Assisted Psychotherapy Offer a New Approach to Chronic Pain? | Dr. Akash Goel
November 20th, 2026
39 mins 35 secs
About this Episode
In this episode of the MAPS Canada Podcast, host Matt Hamel speaks with Dr. Akash Goel, a clinician-investigator, attending anesthesiologist and interventional pain medicine specialist at St. Michael's Hospital and the University of Toronto. His academic pain practice focuses on the application of novel and advanced pain therapeutics, and his research has been featured in leading journals including Anesthesiology, British Journal of Anaesthesia, and The Canadian Journal of Anesthesia.
In this conversation, Dr. Goel discusses emerging research exploring the therapeutic potential of psychedelics and psychedelic-assisted psychotherapy for chronic pain. Drawing on his clinical and research experience, he explains how compounds such as ketamine, MDMA, and psilocybin are being investigated as potential tools for addressing not only the physical experience of pain, but also the psychological, emotional, and relational challenges that frequently accompany it.
Dr. Goel shares findings from his team's research on ketamine-assisted psychotherapy for chronic nerve pain, including how combining ketamine with psychotherapy may help improve pain interference, reduce catastrophic thinking, and support greater engagement with meaningful activities. He also explores the importance of psychological flexibility, acceptance-based approaches, and helping individuals reconnect with a sense of identity that extends beyond their experience of chronic pain.
The conversation also examines emerging research into MDMA-assisted psychotherapy for chronic neuropathic pain, including an ongoing multi-centre clinical trial in Canada. Dr. Goel discusses why MDMA may offer a unique therapeutic opportunity through its effects on empathy and emotional openness, and shares a compelling patient experience that illustrates how psychedelic-assisted therapy may facilitate new perspectives on living with chronic pain.
To learn more about Dr. Goel’s work, visit https://anesthesia.utoronto.ca/faculty/akash-goel
To learn more about the PINNACLE Team research group, visit: https://www.linkedin.com/in/pinnacle-research/
To learn more about Dr. Goel’s involvement with a first-of-its-kind global trial to test the impact of MDMA, commonly known as ecstasy, on chronic nerve pain compared with a placebo, visit: https://unityhealth.to/2024/10/chronic-pain-relief-trial/
==========
Working with partners in government, business, and the community, MAPS Canada is committed to advancing psychedelic medicine by supporting scientific, multidisciplinary research; advocating for drug policy reform; offering public education; and supporting equitable access to legal and regulated psychedelic medicine in Canada.
The Multidisciplinary Association for Psychedelic Studies (MAPS) was formed in the US in 1986, in response to the US Drug Enforcement Agency’s classification of MDMA as Schedule 1 substance, and has been developing medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics since then.
MAPS Canada was founded as a sister organization to MAPS in 2011, and is a registered Canadian non-profit organization. Based in Vancouver and with hundreds of volunteers from across Canada, MAPS Canada is moving forward to become the leading Canadian source of information, resources and advocacy regarding psychedelic medicine and related clinical research, education, and public policy.
Learn More at https://mapscanada.org/about/
MAPS Canada is entirely funded by public donation and your support really makes a difference. Find out about all the ways you can support MAPS Canada’s mission by visiting our donation link https://mapscanada.org/donate/
Support MAPS Canada Podcast